Method for treating conjunctivo-keratitis in cattle

FIELD: veterinary ophthalmology.

SUBSTANCE: the present innovation deals with treating infectious-inflammatory ocular diseases in cattle due to complex treatment with applying antibiotic preparation and biolan, moreover, antibiotic should be introduced into parotid lymphatic center through catheter once or twice daily at the quantity of about 8-10 ml, and biolan - at the dosage of 3-10 mg into the lower conjunctival arch of an eyeball. Such a technique due to taking into account optimal conditions of intraocular liquid circulation provides synergistic effect of the preparations introduced.

EFFECT: higher efficiency of therapy.

1 cl, 1 ex


The invention relates to the field of veterinary medicine, namely to veterinary ophthalmology.

Known methods of treatment of conjunctivitis and keratitis in animals the implementation of retro-bulbar procaine blockade with 0.5%solution of novocaine. In the treatment flegmonoznih conjunctivitis injected novocaine with antibiotics (intravenously, intraarterially, retrobulbarno). The conjunctival SAC moisturize warm disinfectant (furacin), ethacridine lactate, potassium permanganate), antibiotics. Apply liniments and ointments with antibiotics and sulfonamides. When different types of keratitis provide persistent and prolonged use of antibiotics and sulfa drugs, and retro-bulbar procaine blockade (Abrarov V.N., Lebedev A.V. "Veterinary ophthalmology", M, Agropromizdat, 1985, p.95-160) prototype.

However, such treatment does not always produce a rapid recovery. Treatment may last from 1.5 up to 3-4 weeks.

Administration of drugs directly into the lymphatic system increases the effectiveness of therapy. There is a method of treatment of complicated cholecystitis in humans by introducing a solution of the antibiotic in pericholedochal lymph node (2).

Known aminopeptide complex Biolan, which is a set of peptides and amino acids from stabilizer the criterion cellular homeostasis radical scavenging and membrane-stabilizing action (3). Leukocyte adhesion, migration and subsequent activation are those processes that result in the release of free radicals, proteolytic enzymes and other toxic components, which cause severe capillary blood flow. Biolan prevents the formation of oxygen free radicals and protects the microcirculation at the stage of intravascular dehydration (4)contributes to the activation of the lymphatic system.

From the prior art is not known a method of treating conjunctiva-keratitis in cattle by catheterization of the lymphatic vessels coming in the regional lymph node and insertion through them solutions of the antibiotic, while injecting the solution Biolan in the lower fornix of the conjunctiva.

The purpose of the invention is improving the effectiveness of treatment and the expansion of the means of treatment conjunctivitis various etiologies.

In this regard, the task was to develop a method for the treatment of conjunctivitis, keratitis and conjunctivitis different etiology (bacterial, traumatic ulcer, and others) in cattle by endolymphatic administration of antibiotics, promoting regeneration of the cornea and surrounding tissues and restore the function of the patient's eye.

When Pato is Ogii lymphatic system in cattle lymph capillaries and vessels increased 20 times, and lymph nodes, 3-4 times, which allows without any difficulty to find and implement introduction to lymphatic channel drugs. Therefore, their detection and catheterization does not represent the complexity of the veterinary technician of ordinary skill.

Holding endolymphatic of antibiotic therapy in conjunctionwith must be local to increase the use of biologically active substances. Injection lymphotropic drug Biolan in the endolymphatic infusions can prevent complications in the form of lymphorrhea and lymphostasis. Recommended for injection drug Biolan - lower fornix of the conjunctiva of the eyeball, where the accumulation of lymph follicles.

The invention consists in carrying out endolymphatic antibiotic therapy in bacterial, traumatic, ulcerative keratitis and injection lymphotropic drug Biolan.

A method of treating conjunctivitis in cattle is carried out as follows. Previously under local anesthesia with 2%solution of novocaine in the area of the parotid salivary gland in the cranial part of conducting a skin incision from 2 to 4 cm, subcutaneous tissue, superficial dvuhlitrovy fascia and deep fascia, isolated parotid lymph center (peer) and 1-2 Nai is more large lymph vessel. On a dedicated lymphatic vessels impose a purse-string sutures, perform catheterization of the blood vessels and through the catheter administered 1-2 times a day antibiotic solution 1-3% concentration a total of 8-10 ml per one injection. Also, after local anesthesia solution dikaina 0.5% concentration in the lower conjunctival fornix of the eyeball spend once the injection of a solution of biolane at a dose of 3-10 mg per day, which before the introduction dissolved in 2-5 ml of water for injection. In the method of treatment can be used to chloramphenicol, ampicillin, gentamicin and other antibiotics.

The proposed method treated 48 patients with animals (48 eyes) with traumatic ulcers, bacterial conjunctivorhinostomy. Compared with the control group during the inflammatory process was less pronounced, epithelialization occurred in 1 day, recovered transparency, sphericity, the sensitivity of the cornea was significantly reduced pain syndrome, the treatment time averaged 3-4 days, in the control group 14-15 days.

Example 1. Cow No. 3951. Detected surface purulent conjunctivitis right eye. Clinical signs, blood vessels, vascularization of the cornea, photophobia, mucopurulent expiration of the conjunctival SAC. The cornea is opaque, matte, places the second temperature is raised, pain in the eye area.

The animal made treatment (antibiotics, sulfa drugs, corticosteroidsare). The condition has not improved on the 3rd day of treatment. There was a threat of the transition of the pathological process in healthy eyes. Animal vysokoudojnye, valuable, and therefore it was necessary to conduct a more effective treatment.

It was, therefore, carried out the treatment method proposed endolymphatic administration of antibiotics. Previously under local anesthesia with 2%solution of novocaine in the area of the parotid salivary gland in the cranial part of it, had a skin incision 3 cm, subcutaneous tissue, superficial dvuhlitrovy fascia and deep fascia, highlighted the parotid lymph centre (site), and 1 of the largest lymph vessel. This lymphatic vessel has left a purse string suture and performed the catheterization of the vessel. Through the catheter 2 times a day was administered solution of ampicillin with a total number of 9 ml per introduction. Also, after local anesthesia solution dikaina 0.5% concentration in the lower conjunctival fornix of the eyeball conducted once the injection solution of 5 mg biolane dissolved in 3 ml of water for injection.

Infusion of the antibiotic was carried out within two days. On the 3rd day the catheter was removed, the condition of the animal rapidly the ro has improved and returned to normal on the 4th day. The cornea shiny, spherical, transparent, growth of newly formed vessels not.

The way endolymphatic injection of antibiotics and injections aminopeptidase complex Biolan reduces the treatment time up to 3-4 days, while the duration of treatment in a known manner is 14-21 days.

The manifestation of therapeutic effect and restore the basic properties of the cornea occurs much faster on average in the first day. With considerable effectiveness of the treatment is quite simple.

Sources of information

1. Abrarov V.N., Lebedev A.V. Veterinary ophthalmology, M., Agropromizdat, 1985, p.95-160 - prototype.

2. SU 1832012 A1, 16.01.1991.

3. Vagiena, Assalamu, Viglino. Kiniko-hygienic estimation of polypeptide amino acid complex "Biolan". - Report on the research work of the St. Petersburg Academy of Sciences. educat. Academy. Mechnikov. 1995.

4. Nil, Aveny, Dieselboy. Clinical and morphological Parallels the study of lymphatic circulation. - M., 1986.

1. A method of treating conjunctivitis in cattle, including the introduction of a solution of an antibiotic, wherein the pre under local anesthesia with 2%solution of novocaine in the area of the cranial part of the parotid salivary gland spend a skin incision from 2 to 4 cm, subcutaneous tissue, superficial dvuhlitrovy f is scii and deep fascia, allocate the parotid lymph centre and 1-2 of the largest lymph vessel, they impose a purse-string sutures, perform catheterization of the blood vessels and through the catheter administered 1-2 times a day antibiotic solution a total of 8-10 ml per introduction, at the same time after local anesthesia solution dikaina of 0.5%concentration in the lower conjunctival fornix of the eyeball spend a single injection of biolane at a dose of 3-10 mg dissolved in 2-5 ml of water for injection.

2. The method according to claim 1, characterized in that as the use of antibiotics ampicillin, or chloramphenicol or gentamicin.


Same patents:

FIELD: medicine, in particular angiogenesis prophylaxis and treatment.

SUBSTANCE: invention relates to 2-cyclooxygenase inhibitors selected from group containing 4-[5-(4-chlorophenyl)-3-phenyl-1H-pyrazole-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl] benzenesulfonamide; 4-[5-methyl-3-phenyloxazole-4-yl] benzenesulfonamide or pharmaceutically acceptable salts thereof and pharmaceutical composition containing the same in therapeutically effective amount. Said composition are useful in treatment and/or prophylaxis of angiogenesis disorders such as metastasis, eye angiogenesis, diabetic retinopathy, etc. in subjects are needed in such treatment and/or prophylaxis.

EFFECT: new pharmaceuticals for angiogenesis treatment and/or prophylaxis.

5 cl

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with conservative treatment of corneal, retinal and optic nerve's diseases. It includes depositing in ocular tissues of medicinal preparation upon cellular mass. For this purpose it is necessary to apply erythrocytic mass isolated out of a patient to saturate it with medicinal preparation at the ratio of 1:1 due to incubating this mixture at 22-25° C for 20 min. The mixture should be injected into ocular tissues at the nearest distance against pathological focus once/5 d. In case of corneal lesions erythrocytic mass-based preparation should be injected under bulbar conjunctiva perilimbically at the quantity of 0.2-0.3 ml, and at retinal lesions and those of patient's optic nerve - parabulbarly and retrobulbarly at the quantity of 1.0 ml, moreover, medicinal preparation should be chosen out of the following group of solutions: 0.3% gentamicin, or 0.25% derinate, or 1% emoxipine, or 4% taufone. The method is low invasive, of lower immunoreactivity and enables to shorten the terms for inactivation of erythrocytes saturated with medicinal preparation by depositing it at maximal distance against pathological focus.

EFFECT: higher efficiency.

2 ex

FIELD: organic chemistry, medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition comprising S-isomer of compound of the formula (I) or its pharmaceutically acceptable salts and solvates in common with a pharmaceutically acceptable vehicle. Also, invention relates to a method for synthesis of compound S-isomer of the formula (I), and to a method for treatment of disease relating to the group comprising respiratory diseases, allergic diseases, dermatological diseases, gastroenteric diseases and ophthalmic diseases. The composition provides avoiding adverse sedative effects in treatment of indicated diseases.

EFFECT: valuable medicinal properties of compounds.

14 cl, 6 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new nitrogen-containing aromatic derivatives of the general formula:

wherein Ag represents (1) group of the formula:

; (2) group represented by the formula:

or ; (3) group represented by the formula:

; Xg represents -O-, -S-, C1-6-alkylene group or -N(Rg3)- (wherein Rg3 represents hydrogen atom); Yg represents optionally substituted C6-14-aryl group, optionally substituted 5-14-membered heterocyclic group including at least one heteroatom, such as nitrogen atom or sulfur atom, optionally substituted C1-8-alkyl group; Tg1 means (1) group represented by the following general formula:

; (2) group represented by the following general formula: . Other radical values are given in cl. 1 of the invention claim. Also, invention relates to a medicinal agent, pharmaceutical composition, angiogenesis inhibitor, method for treatment based on these compounds and to using these compounds. Invention provides preparing new compounds and medicinal agents based on thereof in aims for prophylaxis or treatment of diseases wherein inhibition of angiogenesis is effective.

EFFECT: improved treatment method, valuable medicinal properties of compounds and agents.

40 cl, 51 tbl, 741 ex

FIELD: medicine, ophthalmology, pediatrics.

SUBSTANCE: method involves irrigation therapy (IT) by retrobulbar catheterization. Before carrying out IT the preparation "Ginkgo biloba" in capsules and age dosage and nasal drops "Semaks" by 1-2 drops for 1 month is prescribed to patient. Then in IT is carried out for 10 days in hospital by administration of cerebrolysin, riboflavin, agapurin, taufon and emoxipine in the dose 0.4 ml of each of them. Preparations are administrated successively, by fractional doses with interval for 2 h in combination with laser-pleoptic treatment at wavelength 0.63 mcm using device "SPEKL" for 10 min, by one procedure per a day for 10 days. After treatment in hospital glutamine and lecithin is prescribed by ambulatory treatment in age doses for 1 month. Method provides the prolonged remission of disease and reduced hospital period due to the complex effect of indicated curative factors on metabolism normalization in nervous cells, their resistance to stress injures, improvement of regenerative and microcirculating processes in eye tissues, frequency-contrast characterization of visual analyzer.

EFFECT: improved treatment method.

1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves intravenous administration of metypred in every other day being in the 1-st and 3-d days the dose is by 500.0 mg, in 5-th and 7-th day - by 250.0 mg, and in 9-th and 10-th day - by 125 mg. In onset of metypred administration dexamethasone in the dose 1.0 ml is administrated by retrobulbar route every day for 10 days. Also, method involves pterygopalatine blockade including dexamethasone, ketorol, emoxipine, lidocaine, dalargin in doses 1.0; 1.0; 1.0; 2.0 ml and 0.001 g every day for 5 days and then 3 blockades in every other day, one blockade per a day. Method expands assortment of therapeutic approaches in treatment of acute optical neuritis in patients with cerebrospinal sclerosis.

EFFECT: improved and enhanced treatment method.

1 tbl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should introduce Botulotoxin A-based Disport preparation into extra-ocular ipsilateral muscle being an antagonist of a paralyzed extra-ocular muscle at the dosage of 10-120 U to be injected into middle part of muscular bursa by leaving about 5 mm , not less against the site of its fixation to sclera. Moreover, additionally, one should inject the preparation suggested either into one or several muscles being contralateral synergists of paralyzed muscles, moreover, one should apply by 10% preparation less into those muscles which are ipsilateral antagonists in comparison with contralateral synergistic ones. The method provides stimulation of afferent nervous impulsation of paralyzed muscle that prevents its hypotrophy.

EFFECT: higher efficiency of therapy.

3 dwg, 3 ex, 12 tbl

FIELD: medicine, ophthalmology, pharmacology, pharmacy.

SUBSTANCE: invention proposes a new agent for applying in therapy of inflammatory diseases of eye anterior site, namely, the silver-containing preparation "Argogel" "Argogel" represents argovite dispersion in polyethylene oxide gel. The preparation shows an antibacterial and virucidal effect and gel base shows additional keratoplastic effect. Invention can be used in therapy of conjunctivitis and retina suppurative ulcers.

EFFECT: valuable medicinal properties of agent.

4 ex

FIELD: pharmaceutical industry.

SUBSTANCE: composition contains cellulose derivatives, glycosaminoglycanes, oligosaccharides, novocain or mercain (both as local anestetics), non-steroidal anti-inflammatory agent, adrenalin, glycerol, and purified water at specified proportions of components.

EFFECT: achieved protection of cornea against mechanical damage due to prevented access of air bubbles and blood under lens, best visualization of fundus of eye, and reduced operation time.

2 ex

FIELD: medical engineering.

SUBSTANCE: viscoelastic has 1.5-2.5% of methylcellulose with 0.02-0.05% thymolol maleate solution and 0.0005-0.001% benzalconium chloride solution as stabilizer being added.

EFFECT: prolonged action; avoided additional drug therapy application.

FIELD: medicine, biomolecular pharmacology.

SUBSTANCE: invention relates to the preparation that represents the product of biological and chemical treatment of vegetable biomass or its waste by using microorganisms. The parent raw represents carbon-containing biomass of vegetable origin wherein carbohydrate moiety represents 5% of the total biomass, not less. Biomass is mixed with water with addition of lactic acid microorganisms taken as a standard ferment with the parent content 0.2-0.5% per 1 l of an aqueous mixture. The mixture is incubated at 40°C for 6 h, not less, under condition of maintaining pH value at the level 6.75 ± 0.05 by addition of ammonium hydroxide. The prepared paste-like mass can be used as the assimilable protein precursor. Also, invention involves characterization of a method for preparing the preparation that involves treatment of the parent vegetable biomass with lactic acid microorganisms and fractional addition of ammonium hydroxide to provide pH value 6.75 ± 0.05. The final product represents the mass comprising the protein assimilable precursors. Invention provides the additional source of assimilable protein precursors.

EFFECT: improved preparing method, valuable properties of preparation.

6 cl, 7 ex

FIELD: agriculture, animal science.

SUBSTANCE: one should inject thymogen intramuscularly about 60-45 d before calving thrice at 24-h-long interval at the dosage of 500 mcg/animal.

EFFECT: higher efficiency.

1 ex, 1 tbl

FIELD: transplantology.

SUBSTANCE: invention discloses pharmaceutical compositions containing substance effective as modulators of biological activity "induced by activation of lymphocytic immunomodulating molecule (AILIM)" (known also as "induced common stimulator (ICOS)"), in particular modulating transduction of AILIM-mediated signal.

EFFECT: achieved suppression, treatment, or prevention of rejection of transplant arising in case of transplantation of organ, a part thereof or tissue.

11 cl, 7 dwg

FIELD: biotechnology, medicine, in particular treatment, prevention and diagnosis of diseases, associated with Neisseria meningitides.

SUBSTANCE: Claimed protein includes one or more N. meningitides protein fragments with known amino acid sequences, wherein said fragment contains one or more antigen determinants and has not more than 1977 amino acid from SEQ ID NO:1 and/or not more than 1531 amino acid from SEQ ID NO:2 which are described in specification with the proviso, that general protein sequence is not characterized by amino acid sequences represented in NO:1 and NO:2. Each claimed protein is encoded by nuclear acid (NA) with nucleotide sequence that defines protein amino acid sequence according to gene code. Peptides and nuclear acid of present invention are useful in drug production for treatment and prophylaxis of infections induced neisseria, as well as in production of diagnostic reagent for detection of neisseria or specific antibodies. Aldo disclosed is peptide- or NA-based pharmaceutical composition in effective amount with acceptable carrier. Said composition is useful for treatment of N. meningitides mediated infection. For prophylaxis composition is applied in vaccine form. Invention makes it possible to overcome diversity of neisseria antigen properties.

EFFECT: improved method for neisseria infection prophylaxis and treatment.

24 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1st and the 8th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1st to the 14th d - procarbazine and prednisolone; moreover, on the 1st and the 8th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, oncology.

SUBSTANCE: the method deals with polychemotherapy and is fulfilled by the following technique: it is necessary to carry out blood sampling in these patients at the quantity of 25 ml: during the 1st d of polychemotherapy one should incubate 5 ml autoblood with 50 mg/sq. m metothrexate, during the 2nd, 3d, 4th and 5th d one should incubate per 5 ml autoblood with 15 mg/sq. m bleomycin daily in thermostat at 37 C for 30 min, carry out application anesthesia and introduce chemopreparations upon autoblood into endonasal tumor component or alternate intratumor introduction of chemopreparations upon autoblood at introducing them into maxillary antrum if it is affected with tumor process. The method provides local concentration and decreased toxicity of chemopreparations due to their intratumor introduction upon autoblood.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

The invention relates to medicine, surgery and anesthesia, and can be used for endolymphatic treatment

The invention relates to obstetrics, in particular to the treatment of placental insufficiency with regard to the metabolic status of women

The invention relates to biotechnology and may find application in Allergy and medicine

FIELD: veterinary science, animals science.

SUBSTANCE: additionally to antibacterial therapy one should intraperitoneally introduce a single injection of 0.5%-novocaine solution at the dosage of 1 ml/kg body weight at pre-dissolved streptomycin there at the dosage of 300000 U. The innovation suggested enables to shorten terms of sickness due to accelerated elimination of agents.

EFFECT: higher efficiency of therapy.

4 ex, 4 tbl